Display options
Cite
Hulhoven R, Michaux JL, Cornu G, et al. A phase II study of vindesine in patients with hematological malignancies. Biomedicine. 1980;33(2):31-2
Hulhoven, R., Michaux, J. L., Cornu, G., Ferránt, A., Bosly, A., Delannoy, A., & Sokal, G. (1980). A phase II study of vindesine in patients with hematological malignancies. Biomedicine / [publiee pour l'A.A.I.C.I.G.], 33(2), 31-2.
Hulhoven, R, et al. "A phase II study of vindesine in patients with hematological malignancies." Biomedicine / [publiee pour l'A.A.I.C.I.G.] vol. 33,2 (1980): 31-2.
Hulhoven R, Michaux JL, Cornu G, Ferránt A, Bosly A, Delannoy A, Sokal G. A phase II study of vindesine in patients with hematological malignancies. Biomedicine. 1980 Apr;33(2):31-2. PMID: 6931617.
Copy Download .nbib Format: NLM
Share it on

Biomedicine. 1980 Apr;33(2):31-2.

A phase II study of vindesine in patients with hematological malignancies.

Biomedicine / [publiee pour l'A.A.I.C.I.G.]

R Hulhoven, J L Michaux, G Cornu, A Ferránt, A Bosly, A Delannoy, G Sokal

PMID: 6931617

Abstract

A phase II protocol associating vindesine and prednisone was used in 47 hematological patients of whom 40 were evaluable. The best results were achieved in relapses of childhood's ALL, with a high proportion of complete remissions and in blastic crises of CML. The efficacy appeared less in relapses of ALL in adults and of malignant lymphoma. The other cases seemed not to respond favorably. The hematological toxicity consisted of leucopenia generally of short duration, but sometimes severe. The neurological toxicity was little and led to reduction of the dosage in only two adults with preexisting neuropathy.

Substances

MeSH terms

Publication Types